{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:25Z","timestamp":1791665965199,"version":"4.3.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["314061271-TRR 205"],"award-info":[{"award-number":["314061271-TRR 205"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Center for Tumor Diseases"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a real-life setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective cohort study of 54 patients with advanced ACC receiving ICI as compassionate use at 6 German reference centres between 2016 and 2022.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAE) were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In 52 patients surviving at least 4 weeks after initiation of ICI, ORR was 13.5% (6-26) and DCR was 24% (16-41). PFS was 3.0 months (95% CI, 2.3-3.7). In all patients, median OS was 10.4 months (3.8-17). 17 TRAE occurred in 15 patients, which was associated with a longer PFS of 5.5 (1.9-9.2) vs 2.5 (2.0-3.0) months (HR 0.29, 95% CI, 0.13-0.66, P = 0.001) and OS of 28.2 (9.5-46.8) vs 7.0 (4.1-10.2) months (HR 0.34, 95% CI, 0.12-0.93). Positive tissue staining for programmed cell death ligand 1 (PD-L1) was associated with a longer PFS of 3.2 (2.6-3.8) vs 2.3 (1.6-3.0, P &amp;lt; 0.05) months. Adjusted for concomitant mitotane use, treatment with nivolumab was associated with lower risk of progression (HR 0.36, 0.15-0.90) and death (HR 0.20, 0.06-0.72) compared to pembrolizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In the real-life setting, we observe a response comparable to other second-line therapies and an acceptable safety profile in ACC patients receiving different ICI. The relevance of PD-L1 as a marker of response and the potentially more favourable outcome in nivolumab-treated patients require confirmation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvad054","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T15:28:29Z","timestamp":1685546909000},"page":"485-493","source":"Crossref","is-referenced-by-count":27,"title":["Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3499-5910","authenticated-orcid":false,"given":"Hanna","family":"Remde","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Josef-Schneider-Stra\u00dfe 2, 97080 W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schmidt-Pennington","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health , Berlin 10117 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Reuter","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Josef-Schneider-Stra\u00dfe 2, 97080 W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6315-4176","authenticated-orcid":false,"given":"Laura-Sophie","family":"Landwehr","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Josef-Schneider-Stra\u00dfe 2, 97080 W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health , Berlin 10117 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Lahner","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, University Hospital Duisburg-Essen , Hufelandstra\u00dfe 55, 45147 Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8283-7861","authenticated-orcid":false,"given":"Otilia","family":"Kimpel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Josef-Schneider-Stra\u00dfe 2, 97080 W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Josef-Schneider-Stra\u00dfe 2, 97080 W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Laubner","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Medicine II, Faculty of Medicine, Medical Centre University of Freiburg, University of Freiburg , Hugstetter Stra\u00dfe 55, 79106 Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schreiner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV, University Hospital Munich, Ludwig-Maximilians-University M\u00fcnchen , Ziemssenstra\u00dfe 5, 80336 M\u00fcnchen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Bojunga","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 1, Division of Endocrinology, Goethe University Frankfurt, Faculty 16 Medicine , Theodor-Stern-Kai 7, 60596 Frankfurt am Main , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kircher","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg , Josef-Schneider-Str. 2, 97080 W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina Alisa","family":"Kunze","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health , Charit\u00e9platz 1, 10117 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pohrt","sequence":"additional","affiliation":[{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin , Charit\u00e9platz 1, 10117 Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Veronica","family":"Teleanu","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases Heidelberg and German Cancer Research Center, Im Neuenheimer Feld 460 , Heidelberg 69120 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[{"name":"Computational Oncology Group, Molecular Precision Oncology Program, National Centre for Tumour Diseases (NCT), Heidelberg and German Cancer Research Centre (DKFZ) , Im Neuenheimer Feld 580, 69120 Heidelberg , Germany"},{"name":"Pattern Recognition and Digital Medicine Group, Heidelberg Institute for Stem cell Technology and Experimental Medicine (HI-STEM) gGmbH , Im Neuenheimer Feld 280, 69120 Heidelberg , Germany"},{"name":"German Cancer Consortium, Im Neuenheimer Feld 280 , Heidelberg 69120 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pathologie, Universit\u00e4tsklinikum Heidelberg, Im Neuenheimer Feld 224 , Heidelberg 69120 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Glimm","sequence":"additional","affiliation":[{"name":"Department for Translational Medical Oncology, National Centre for Tumour Diseases (NCT\/UCC) , Dresden , Germany"},{"name":"Translational Medical Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden , Dresden , Germany"},{"name":"Translational Functional Cancer Genomics, National Centre for Tumour Diseases (NCT) and German Cancer Research Center (DKFZ) , Heidelberg , Germany"},{"name":"Department for Translational Medical Oncology (DD05), National Center for Tumor Diseases Dresden (NCT\/UCC), German Cancer Consortium (DKTK) , Fetscherstra\u00dfe 74\/PF 64, 01307 Dresden , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Fr\u00f6hling","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases Heidelberg and German Cancer Research Center, Im Neuenheimer Feld 460 , Heidelberg 69120 , Germany"},{"name":"German Cancer Consortium, Im Neuenheimer Feld 280 , Heidelberg 69120 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6170-6398","authenticated-orcid":false,"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Josef-Schneider-Stra\u00dfe 2, 97080 W\u00fcrzburg , Germany"},{"name":"Comprehensive Cancer Center Mainfranken, University of W\u00fcrzburg , W\u00fcrzburg, Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-3155","authenticated-orcid":false,"given":"Knut","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology & Metabolism, Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin, and Berlin Institute of Health , Berlin 10117 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kroiss","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of W\u00fcrzburg , Josef-Schneider-Stra\u00dfe 2, 97080 W\u00fcrzburg , Germany"},{"name":"Department of Internal Medicine IV, University Hospital Munich, Ludwig-Maximilians-University M\u00fcnchen , Ziemssenstra\u00dfe 5, 80336 M\u00fcnchen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,1]]},"reference":[{"issue":"11","key":"2023062901154072300_lvad054-B1","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO\u2013EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol."},{"issue":"5","key":"2023062901154072300_lvad054-B2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"issue":"4","key":"2023062901154072300_lvad054-B3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1210\/jc.2016-2894","article-title":"Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma","volume":"102","author":"Berruti","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023062901154072300_lvad054-B4","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"23","key":"2023062901154072300_lvad054-B5","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"2023062901154072300_lvad054-B6","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1210\/jc.2017-01624","article-title":"Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors","volume":"102","author":"Henning","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023062901154072300_lvad054-B7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1677\/ERC-09-0281","article-title":"Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study","volume":"17","author":"Sperone","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2023062901154072300_lvad054-B8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1023\/A:1008377915129","article-title":"Streptozocin and o, p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use","volume":"11","author":"Khan","year":"2000","journal-title":"Ann Oncol"},{"issue":"3-4","key":"2023062901154072300_lvad054-B9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12672-020-00385-3","article-title":"Advanced adrenocortical carcinoma (ACC): a review with focus on second-line therapies","volume":"11","author":"Ardolino","year":"2020","journal-title":"Horm Cancer"},{"issue":"5","key":"2023062901154072300_lvad054-B10","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","article-title":"Objective response and prolonged disease control of advanced adrenocortical carcinoma with cabozantinib","volume":"105","author":"Kroiss","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023062901154072300_lvad054-B11","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa069","article-title":"Salvage therapy with multikinase inhibitors and immunotherapy in advanced adrenal cortical carcinoma","volume":"4","author":"Miller","year":"2020","journal-title":"J Endocr Soc"},{"issue":"2-03","key":"2023062901154072300_lvad054-B12","first-page":"109","article-title":"Advanced adrenocortical carcinoma\u2014what to do when first-line therapy fails?","volume":"127","author":"Megerle","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"2023062901154072300_lvad054-B13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN Guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2023062901154072300_lvad054-B14","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023062901154072300_lvad054-B15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 Blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2023062901154072300_lvad054-B16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2023062901154072300_lvad054-B17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2023062901154072300_lvad054-B18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1908771","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538","volume":"10","author":"Klein","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"2023062901154072300_lvad054-B19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000469","article-title":"Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma","volume":"8","author":"Landwehr","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2023062901154072300_lvad054-B20","doi-asserted-by":"crossref","first-page":"v128","DOI":"10.1093\/annonc\/mdx367.020","article-title":"Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers","volume":"28","author":"Diaz","year":"2017","journal-title":"Ann Oncol."},{"issue":"1","key":"2023062901154072300_lvad054-B21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s40425-018-0342-x","article-title":"Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2023062901154072300_lvad054-B22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2023062901154072300_lvad054-B23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"1","key":"2023062901154072300_lvad054-B24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1148\/radiol.2020200443","article-title":"Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis","volume":"297","author":"Hyo","year":"2020","journal-title":"Radiology"},{"issue":"4","key":"2023062901154072300_lvad054-B25","doi-asserted-by":"crossref","first-page":"e1348","DOI":"10.1210\/clinem\/dgab895","article-title":"Targeting 11-beta hydroxylase with [131I]IMAZA: a novel approach for the treatment of advanced adrenocortical carcinoma","volume":"107","author":"Hahner","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"30","key":"2023062901154072300_lvad054-B26","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2023062901154072300_lvad054-B27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"8","key":"2023062901154072300_lvad054-B28","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/ERC-21-0048","article-title":"Adrenal tumors provide insight into the role of cortisol in NK cell activity","volume":"28","author":"Greenstein","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2023062901154072300_lvad054-B29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2023062901154072300_lvad054-B30","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023062901154072300_lvad054-B31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001009","article-title":"Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma","volume":"8","author":"Bedrose","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvad054\/50500096\/lvad054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/6\/485\/50735492\/lvad054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/188\/6\/485\/50735492\/lvad054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T01:16:08Z","timestamp":1688001368000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/188\/6\/485\/7187724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvad054","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,6,1]]}}}